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LETTER TO THE EDITOR
Sir-Thyss and colleagues recently reported in this journal
(Thyss et al., 1989) the CSF accumulation of folate after
folinic acid rescue in patients receiving systemic methotrex-
ate. The general conclusion was that the repeated administra-
tion of folinic acid resulted in a steady increase in the CSF
folate concentration (as 5-methyltetrahydrofolate, not folinic
acid). The implication is that high dose methotrexate therapy
with folinic acid rescue may selectively rescue cells in the
CSF because methotrexate passes the blood-brain barrier
poorly, whereas the folate content increased to 4-5 times
below the lower limits of detection with the assay described
and had a very long terminal half life. Since it has already
been shown that intermediate dose methotrexate is not as
effective as IT therapy in preventing central nervous system
leukaemia, this point assumes even more significance. In this
regard, we measured the CSF folate 6 h after a single 10 mg
dose of folinic acid was given orally to children with ALL
who were having diagnostic lumbar puncture. We compared
this value to CSF folate in children not receiving folinic acid
and to the CSF folate in patients having lumbar punctures
for other reasons (e.g. myelogram). The results are shown in
Table I.
Table I CSF folate in children
Patient group n Folate (mean ng ml-')a(range)
ALL in remission (no 65 21.3 (10-33)
folinic acid)
Control 9 18.2 (11-26)
(non-malignant disease)
ALL, 6 h post 10 mg 6 60.0 (45-75)
folinic acid given p.o.
a Conversion to molar concentration, as reported by Thyss et al.,
yields values of 40 nM, 40 nm and 135 nm respectively for the three
groups.
The CSF folate in the two 'control' populations deter-
mined by radio-ligand binding assay (Zettner & Duly, 1974)
is equivalent to the data presented by others using different
assay methodology (Wells & Casey, 1967). There was no
difference between the two groups. The CSF folate in the six
children who received folinic acid, however, was significantly
elevated nearly 3-4-fold. Since we only did one time point
we cannot comment on whether it was a peak value. We
chose 6 h for convenience; serendipitously, a time when
Thyss et al. did find a maximum value.
Thus our data on an additional six children with ALL
confirm the observations reported by Thyss et al. Moreover,
using a more sensitive assay for 5-methyltetrahyrofolate
(10-9M) we showed that the folate in the CSF increased at
least 3-4-fold over normal after only one dose of oral folinic
acid.
Since the half life of the folate in the CSF was >3 days
(Thyss et al., 1989) and we showed that only one dose of
10 mg of folinic acid given orally (compared to 100 or
250 mg given intravenously here) raised CSF folate, repetitive
dosing of folinic acid, such as given in standard intermediate
and high dose MTX regimens, may significantly raise the
CSF folate for prolonged time. Therefore, we concur that the
use of repeated oral folinic acid to rescue patients from the
systemic side effects of methotrexate should be of concern in
the design of treatment regimens in which anti-fols are used
to treat or prevent malignant disease in the CNS.
Yours etc.
B.A. Kamen & T. Vietti,
University of Texas,
Southwestern Medical Center,
5323 Harry Hines Blvd,
Dallas,
Texas 75235-9063,
USA.
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